Sarepta CEO Doug Ingram said it is important the company maintains a “positive working relationship” with the FDA.

The FDA appears to have won its staring contest with Sarepta over shipments of Elevidys, after the company blinked and agreed ...

The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.